Mounting evidence suggests that the inflammatory processes in the brain contribute to the pathologies of Parkinson’s, Alzheimer’s and HIV-associated neurocognitive disorders.
With that in mind, and in preparation for clinical trials, an agreement has been signed to initiate research that looks at GB Science‘s cannabis-containing complex formulas for Parkinson’s Disease.
The study will be done in collaboration with Dr. Norbert Kaminski, Professor of Pharmacology & Toxicology at Michigan State University.
“GB Sciences is honored to be working with Dr. Kaminski on this project. He pioneered studies of the effects of cannabis on the immune system,” said Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, in a release.
“More recently, Dr, Kaminski’s work has centered around the immune modulating effects of cannabis consumption on HIV/AIDS patients,” added Small-Howard. “In 2017, he demonstrated a relationship between cannabis use and improved brain health in HIV/AIDS patients who used cannabis versus those who did not. Dr. Kaminski has further theorized that cannabis use by HIV/AIDS patients may reduce their risk of HIV-Associated Neurocognitive Disorder (HAND) by reducing levels of inflammatory white blood cells in their brains. This same neuroinflammation may be a major contributing factor in a number of related neurological disorders such as Parkinson’s disease and Alzheimer’s disease.”
Dr. Kaminski will study the toxicology, anti-inflammatory properties and immunomodulatory activity of GB Sciences’ proprietary cannabis-based neuroprotective compounds using a diverse array of assays employing human primary white blood cells.
GB Sciences holds a formidable Intellectual Properties portfolio and has engaged the cooperation of top research Universities and CRO’s to maximize its potential.
Given the breadth and depth of the disease states covered by the portfolio, the Company has adopted a ‘Best of Breed’ approach to identify, engage, and develop the most effective team to research and create the needed formulations on a project by project basis.
“GB Sciences is very fortunate to be working with Dr. Kaminski on this important research and development project on our lead therapeutic compounds,” said John Poss, CEO and Chairman of GB Sciences, Inc. “Our company is committed to working with top universities and CRO’s to achieve our goal of helping to unlock the therapeutic potential of cannabis.”
MSU has begun testing GB Sciences’ neuroprotective compounds at their Institute for Integrative Toxicology, where Dr. Kaminski serves as Director.
